{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:25:30Z","timestamp":1793298330345,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL126911, R01HL137734, R01HL137794, R01HL141434, R01HL136660, U54HL143541"],"award-info":[{"award-number":["R01HL126911, R01HL137734, R01HL137794, R01HL141434, R01HL136660, U54HL143541"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG060529-01"],"award-info":[{"award-number":["R21AG060529-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11606-020-05777-3","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T11:02:20Z","timestamp":1586862140000},"page":"2329-2337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents"],"prefix":"10.1007","volume":"35","author":[{"given":"Matthew","family":"Alcusky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tjia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Hume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate L.","family":"Lapane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"5777_CR1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med."},{"key":"5777_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med."},{"key":"5777_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, ARISTOTLE Committees and Investigators, et al.. Apixaban versus warfarin. N Engl J Med. 2011;365:981\u2013992.","journal-title":"N Engl J Med."},{"issue":"8","key":"5777_CR4","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1161\/STROKEAHA.117.017474","volume":"48","author":"CI Coleman","year":"2017","unstructured":"Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017;48(8):2142\u20132149.","journal-title":"Stroke."},{"key":"5777_CR5","doi-asserted-by":"crossref","unstructured":"Lip GY, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12):2933\u20132944.","DOI":"10.1161\/STROKEAHA.118.020232"},{"key":"5777_CR6","doi-asserted-by":"publisher","first-page":"e008643","DOI":"10.1161\/JAHA.118.008643","volume":"7","author":"BK Martinez","year":"2018","unstructured":"Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018;7: e008643.","journal-title":"J Am Heart Assoc"},{"key":"5777_CR7","doi-asserted-by":"crossref","unstructured":"Alcusky M, McManus DD, Hume AL, Fisher M, Tjia J, Lapane KL. Changes in Anticoagulant Utilization among United States Nursing Home Residents with Atrial Fibrillation from 2011-2016. J Am Heart Assoc. 2019;7(9):e012023","DOI":"10.1161\/JAHA.119.012023"},{"key":"5777_CR8","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","volume":"69","author":"X Yao","year":"2017","unstructured":"Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017;69:2779\u20132790.","journal-title":"J Am Coll Cardiol."},{"key":"5777_CR9","unstructured":"Saliba S, Buchcanan J. Development & Validation of a Revised Nursing Home Assessment Tool: MDS 3.0. Rand Health Corporation. 2008. Centers for Medicare and Medicaid Services Contract No. 500-00-0027."},{"key":"5777_CR10","doi-asserted-by":"crossref","unstructured":"Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560\u20136.","DOI":"10.1002\/pds.2109"},{"issue":"1","key":"5777_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.thromres.2010.03.009","volume":"126","author":"RH White","year":"2010","unstructured":"White RH, Garcia M, Sadeghi B, et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res. 2010;126(1):61\u201367.","journal-title":"Thromb Res."},{"key":"5777_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCOUTCOMES.113.000743","volume":"7","author":"H Kumamaru","year":"2014","unstructured":"Kumamaru H, Judd SE, Curtis JR, et al. Validity of claims-based stroke algorithms in contemporary medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims. Circ Cardiovasc Qual Outcomes. 2014;7:611\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"1","key":"5777_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","volume":"148","author":"Y Kiyota","year":"2004","unstructured":"Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of medicare claims-based diagnosis of acute myocardial infarction: Estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99\u2013104.","journal-title":"Am Heart J."},{"key":"5777_CR14","unstructured":"Centers for Medicare and Medicaid Services (CMS). ICD-10-CM and GEMs. 2016. from https:\/\/www.cms.gov\/Medicare\/Coding\/ICD10\/2016-ICD-10-CM-and-GEMs.html. Accessed September 5, 2018"},{"issue":"2","key":"5777_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263\u2013272.","journal-title":"Chest."},{"key":"5777_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","volume":"58","author":"MC Fang","year":"2011","unstructured":"Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395\u2013401.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"5777_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","volume":"91","author":"S Bangalore","year":"2016","unstructured":"Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. Mayo Clin Proc. 2016;91(1):51\u201360.","journal-title":"Mayo Clin Proc."},{"issue":"9894","key":"5777_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769\u201379.","journal-title":"Lancet."},{"key":"5777_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.amjcard.2014.05.037","volume":"114","author":"GR Quinn","year":"2014","unstructured":"Quinn GR, Singer DE, Chang Y, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014;114:583\u20136.","journal-title":"Am J Cardiol."},{"issue":"5","key":"5777_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","volume":"127","author":"AL Dans","year":"2013","unstructured":"Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127(5):634\u201340.","journal-title":"Circulation."},{"key":"5777_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","volume":"210","author":"HG Yebyo","year":"2019","unstructured":"Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18\u201328.","journal-title":"Am Heart J."},{"issue":"2","key":"5777_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2005.04.029","volume":"46","author":"WC Winkelmayer","year":"2005","unstructured":"Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from medicare claims data: A validation study. Am J Kidney Dis. 2005;46(2):225\u2013232.","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"5777_CR23","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/MLR.0000000000000334","volume":"55","author":"KS Thomas","year":"2017","unstructured":"Thomas KS, Dosa D, Wysocki A, Mor V. The Minimum Data Set 3.0 Cognitive Function Scale. Med Care. 2017;55(9):e68-e72.","journal-title":"Med Care."},{"issue":"11","key":"5777_CR24","doi-asserted-by":"publisher","first-page":"M546","DOI":"10.1093\/gerona\/54.11.M546","volume":"54","author":"J Morris","year":"1999","unstructured":"Morris J, Fries B, Morris S. Scaling ADLs with the MDS. J Gerontol A Biol Sci Med Sci. 1999;54(11):M546-M553.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"5777_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.archger.2017.08.005","volume":"73","author":"JE Kurichi","year":"2017","unstructured":"Kurichi JE, Bogner HR, Streim JE, et al. Predicting 3-year mortality and admission to acute-care hospitals, skilled nursing facilities, and long-term care facilities in Medicare beneficiaries. Arch Gerontol Geriatr. 2017;73:248\u2013256.","journal-title":"Arch Gerontol Geriatr."},{"key":"5777_CR26","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2147\/CLEP.S174807","volume":"10","author":"S Hapca","year":"2018","unstructured":"Hapca S, Guthrie B, Cvoro V, et al. Mortality in people with dementia, delirium, and unspecified cognitive impairment in the general hospital: prospective cohort study of 6,724 patients with 2 years follow-up. Clin Epidemiol. 2018;10:1743\u20131753.","journal-title":"Clin Epidemiol."},{"issue":"6","key":"5777_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.japh.2017.06.002","volume":"57","author":"N Leelakanok","year":"2017","unstructured":"Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc (2003). 2017;57(6):729\u2013738.e10.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"5777_CR28","doi-asserted-by":"crossref","unstructured":"Wyss R, Girman CJ, LoCasale RJ, Brookhart AM, St\u00fcrmer T. Variable Selection for Propensity Score Models When Estimating Treatment Effects on Multiple Outcomes: a Simulation Study. Pharmacoepidemiol Drug Saf. 2013;22(1):77\u201385.","DOI":"10.1002\/pds.3356"},{"issue":"6","key":"5777_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/pds.2098","volume":"20","author":"AR Patrick","year":"2011","unstructured":"Patrick AR, Schneeweiss S, Brookhart MA, et al. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf. 2011;20(6):551\u20139.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"12","key":"5777_CR30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","volume":"163","author":"MA Brookhart","year":"2006","unstructured":"Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, St\u00fcrmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149\u20131156.","journal-title":"Am J Epidemiol."},{"issue":"8","key":"5777_CR31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/pds.3574","volume":"23","author":"MS Ali","year":"2014","unstructured":"Ali MS, Groenwold RH, Pestman WR, et al. Propensity score balance measures in pharmacoepidemiology: a simulation study. Pharmacoepidemiol Drug Saf. 2014;23(8):802\u201311.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"5777_CR32","unstructured":"Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022512s000lbl.pdf. Accessed June 25, 2017."},{"key":"5777_CR33","unstructured":"Xarelto [package insert]. Leverkusen, Germany: Janssen. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/022406s000lbl.pdf. Accessed June 25, 2017."},{"key":"5777_CR34","unstructured":"Eliquis [package insert]. Princeton, New Jersey: Bristol Myers Squibb. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf. Accessed September 1, 2017."},{"issue":"4","key":"5777_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/sim.4780100409","volume":"10","author":"H Petri","year":"1991","unstructured":"Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577\u201381.","journal-title":"Stat Med."},{"key":"5777_CR36","unstructured":"Yale New Haven Health Services Corporation\/Center for Outcomes Research & Evaluation. 2014 Measures updates and specifications report hospital-level 30-day risk-standardized readmission measures. 2014. Available at: http:\/\/altarum.org\/sites\/default\/files\/uploaded-publicationfiles\/Rdmsn_Msr_Updts_HWR_0714_0.pdf. Accessed February 27, 2019."},{"issue":"3","key":"5777_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/jhm.890","volume":"6","author":"PK Lindenauer","year":"2011","unstructured":"Lindenauer PK, Normand SLT, Drye EE, et al. Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia. J Hosp Med. 2011;6(3):142\u2013150.","journal-title":"J Hosp Med."},{"key":"5777_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J Mant","year":"2007","unstructured":"Mant J, Hobbs F, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation: a randomized controlled trial. Lancet. 2007;370:493\u2013503.","journal-title":"Lancet."},{"issue":"24","key":"5777_CR39","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, et al. ORBIT-AF Investigators and Patients. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68(24):2597\u20132604.","journal-title":"J Am Coll Cardiol."},{"key":"5777_CR40","doi-asserted-by":"crossref","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019. (19)30209\u20138.","DOI":"10.1161\/CIR.0000000000000665"},{"issue":"9","key":"5777_CR41","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/phar.2158","volume":"38","author":"J Zhu","year":"2018","unstructured":"Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. Pharmacotherapy. 2018;38(9):907\u2013920.","journal-title":"Pharmacotherapy."},{"key":"5777_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ahj.2017.03.024","volume":"189","author":"BA Steinberg","year":"2017","unstructured":"Steinberg BA, Shrader P, Thomas L, et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2017;189:40\u201347.","journal-title":"Am Heart J"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-05777-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-020-05777-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-05777-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T23:30:52Z","timestamp":1722727852000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-020-05777-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5777"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-05777-3","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"10 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DDM has received research grant funding from Bristol-Myers Squibb, Boeringher-Ingelheim, Pfizer, Samsung, Philips Healthcare, Philips, Biotronik, and FlexCon and has received consultancy fees from Bristol-Myers Squibb, Pfizer, Flexcon, Boston Biomedical Associates. Other authors have no relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}